Browse more peptide research, methods and limitations.
GLP-1-secreting engineered MSCs enhanced β-cell survival and improved glycemic control in T1D mice, combining cell therapy regenerative potential with continuous GLP-1 peptide delivery.
Huang, Zheng; Zhang, Yuyi; Tian, Jingwen; Song, Pengbo; Tong, Cailing; Qi, Zhongquan ·
Plant-derived peptides can regulate both ACE-1 (antihypertensive) and ACE-2 (metabolic/antiviral), offering multi-target natural alternatives to synthetic drugs with favorable safety profiles.
Huang, Zhenyu; Shao, Qiong; Li, Pengze; Wang, Jian; Cai, Ming; Ma, Jiayue; Yang, Kai; Bu, Tingting; Yang, Huimin ·
GLP-1 RAs and SGLT2i showed different colorectal tumor risk profiles, with differential effects by tumor location and patient characteristics in a large T2D cohort.
Hung, Chao-Ming; Zeng, Bing-Yan; Hsu, Chih-Wei; Chen, Po-Huang; Sun, Cheuk-Kwan; Carvalho, Andre F; Stubbs, Brendon; Chen, Yen-Wen; Chen, Tien-Yu; Lei, Wei-Te; Chen, Jiann-Jy; Shiue, Yow-Ling; Su, Kuan-Pin; Liang, Chih-Sung; Tseng, Ping-Tao ·
Preoperative GLP-1 RA exposure was not associated with increased risk of postoperative AKI after metabolic and bariatric surgery.
Hung, Kuo-Chuan; Chang, Li-Chen; Tan, Ping-Heng; Hsu, Chih-Wei; Lai, Yi-Chen; Wu, Jheng-Yan; Chen, I-Wen ·
DKD treatment evolved over 30 years from RAAS inhibitors alone to four pillars (RAAS, SGLT2i, finerenone, GLP-1 RA), each targeting distinct mechanisms: hemodynamic, glucose-mediated, mineralocorticoid, and metabolic/inflammatory.
Husain-Syed, Faeq; Yuecel, Goekhan; Daschner, Clara; Jochims, Jan; Yazdani, Babak ·
Tirzepatide has demonstrated cardiovascular safety in T2D and obesity. Active cardioprotection (MACE reduction) is being assessed in ongoing dedicated cardiovascular outcome trials.
Huston, Jessica; Orey, Dontia; Ashchi, Andrew; Lachapelle, Andrea Ashchi; Genovese, Ariana; Jackson, Jenna; Ashchi, Ramsey; Ashchi, Towfeeq; Ashchi, Majdi; Sutton, David; Deeb, Wasim; Goldfaden, Rebecca F ·
LMWCP 1000 mg/day: 54× higher GPH AUC vs general collagen. Significant vs placebo improvements: cellulite severity, dermal-subcutaneous border, skin roughness, skin elasticity (weeks 12+24), hair diameter (week 24).
Hwang, Sehee; Won, Jihyun; Kim, Suyeon; Kang, Wonku; Park, Miyoung ·
GLP-1 RA vs DPP-4i: cirrhosis/decompensation HR 0.684 (0.615-0.762). GLP-1 vs insulin (obese): HR 0.327 (0.263-0.406). GLP-1 vs insulin (non-obese): HR 0.222 (0.133-0.373). GLP-1 vs metformin: HR 0.87 (NS).
Hwang, Soo Young; Hsieh, Pinghsin; Díaz, Luis Antonio; Goodman, Russell P; Schaefer, Esperance A; Wong, Robert J; Luther, Jay; Zhang, Wei ·
Eptinezumab: MMD reduction -6.9 at 24 weeks; ≥50% responder: 48.2%; >40% optimal/modest control; early 3-month response predicted 6-month outcome; AEs 4.7%; satisfaction 94% at 12 months.
Iannone, Luigi Francesco; Piella, Elisa Maria; Montisano, Danilo Antonio; Fasano, Carla; Sebastianelli, Gabriele; Coppola, Gianluca; Ferrandi, Delfina; Lanni, Claudia; Prudenzano, Maria Pia; de Tommaso, Marina; Merlo, Paola; De Cesaris, Francesco; Chiarugi, Alberto; Munafò, Antonio; Pistoia, Francesca; Ornello, Raffaele; Doretti, Alberto; Grazzi, Licia; Lo Castro, Flavia; De Icco, Roberto; Vaghi, Gloria; Avino, Gianluca; Romozzi, Marina; Calabresi, Paolo; Battistini, Stefania; Rufa, Alessandra; Albanese, Maria; Trimboli, Michele; Carlucci, Giovanna; Silvestro, Marcello; Russo, Antonio; Rainero, Innocenzo; Valente, Maria Rosaria; Fofi, Luisa; Marcosano, Marilena; Geppetti, Pierangelo; Altamura, Claudia; Vernieri, Fabrizio; Tassorelli, Cristina; Sacco, Simona; Guerzoni, Simona ·
D-allulose: reduced visceral fat, improved insulin resistance, ameliorated glucose intolerance in OVX mice. Effects abolished in GLP-1R KO mice, confirming GLP-1-dependent mechanism. Sucrose worsened metabolism only in OVX (not sham) mice.
Iba, Kengo; Kyo, Miharu; Ishihara, Hirotaka; Nagao, Aki; Kawabe, Misaki; Ohbayashi, Kento; Yada, Toshihiko; Iwasaki, Yusaku ·
GLP-1R agonists: cardiovascular protection via anti-inflammatory, anti-atherosclerotic, cardiac-specific mechanisms. Proven in T2D (LEADER, SUSTAIN-6), obesity (SELECT), CKD (FLOW), HFpEF (STEP-HFpEF). Weight-independent benefits.
Ibe, Tatsuro; Borlaug, Barry A ·
11 studies, 27,143 patients: no significant differences in pseudoarthrosis (OR 1.29, NS), SSI (0.97), pneumonia (1.19), DVT (1.34), AKI (1.27), readmission (1.06), or ED visits (0.95) between GLP-1 users and non-users.
Ibrahim, Syed; Durrani, Abrahim; Ibrahim, Muhammad Talal; Kuttner, Nicolas; Glivar, Phillip; Singh, Varun Kumar; Yu, Elizabeth ·
<3 kDa whey protein intestinal peptides (from β-La and α-La): strongest CCK stimulation in STC-1 cells. In silico: ACE-inhibitory, DPP-IV-inhibitory, antioxidant, antibacterial activities. ENSAEPE motif identified.
Ignot-Gutiérrez, Anaís; Arellano-Castillo, Orlando; Serena-Romero, Gloricel; Alvarado-Olivarez, Mayvi; Guajardo-Flores, Daniel; Martínez, Armando J; Cruz-Huerta, Elvia ·
12-month cIMT reduction: combo -10.7%, liraglutide -8.2%, empagliflozin -5.6%, insulin -1.7%. Aβ1-40 reduction: combo -50.7%, liraglutide -52.1%, empagliflozin -40.3%, insulin -30.7%. MDA: combo -23.7%, insulin -9.3%. cIMT regression correlated with Aβ and MDA reductions.
Ikonomidis, Ignatios; Papageorgiou, Anastasios; Pavlidis, George; Georgiopoulos, Georgios; Katogiannis, Konstantinos; Maratou, Eirini; Thymis, John; Pliouta, Loukia; Kountouri, Aikaterini; Korakas, Emmanouil; Kostelli, Gabriella; Parissis, John; Nikolaou, Panagiota Efstathia; Andreadou, Ioanna; Lambadiari, Vaia ·
≥50% responder: 54% (6 months), 52% (12 months). 3-month response predicted 6-month response. Migraine symptoms/aura improved through 5 months. Injection site reactions: 24%→11%. Satisfaction: 94% at 12 months. 150 Japanese patients.
Imai, Shungo; Ihara, Keiko; Takahashi, Nobuyuki; Ohtani, Seiya; Watanabe, Narumi; Iba, Chisato; Ishizuchi, Kei; Takemura, Ryo; Nakahara, Jin; Hori, Satoko; Takizawa, Tsubasa ·
USPs (≤7-8 aa) self-assemble into biocompatible hydrogels with shear-thinning, rapid gelation, and mechanical tunability suitable for 3D bioprinting, with applications across tissue engineering, wound healing, and drug delivery.
In, Davina; Miliotou, Androulla N; Siafaka, Panoraia I; Sarigiannis, Yiannis ·
Metabolic disorders amplify cardiomyopathy through energetic imbalance, inflammation, and fibrosis. SGLT2i and GLP-1 RA promote reverse remodeling by targeting these converging mechanisms with pleiotropic effects beyond neurohormonal blockade.
Indennidate, Carla; Perencin, Brigitta; Di Maso, Vittorio; Buda, Iris; Candido, Riccardo; Sinagra, Gianfranco; Merlo, Marco ·
Floss-based vaccination: delivered peptide nanoparticles through gingival sulcus → stimulated local LN, increased CD4+ T cells, boosted antibody-secreting cells in bone marrow → durable protection against lethal influenza. Superior to sublingual, comparable to intranasal. Human feasibility confirmed.
Ingrole, Rohan S J; Shakya, Akhilesh Kumar; Joshi, Gaurav; Lee, Chang Hyun; Nesovic, Lazar D; Compans, Richard W; Gill, Harvinder Singh ·
Prebiotics → SCFA fermentation → FFAR2/3 activation → GLP-1/GLP-2/PYY release → improved insulin secretion, gut barrier, stomach emptying, appetite. Meta-analyses: modest HbA1c and FPG reductions. Resistant starch and inulin most consistent.
Irfan, Zainab; Halder, Jitu; Giri, Sumon; Molla, Ekbal Ali; Khanam, Sofia ·
GLP-1 RA: multiple myeloma risk HR 0.64 (p=0.01), preserved in BMI>30 and HbA1c>8% subgroups. SGLT2i: increased mortality in MM (HR 2.27, p<0.001) and AML (HR 2.00, p=0.006). No significant effects for CML or MDS.
Irons, Eric Edward; Pfeil, Keri Ann; Perez, Jaime Abraham; van Besien, Koen ·
Japanese adults (n=102): tirzepatide 5/10/15 mg achieved -12.0/-22.4/-22.1% weight loss vs -0.3% placebo at 72 weeks. ≥5% loss: 91.7/100/96.6% vs 15.4%. Significant cardiometabolic improvements. No new safety signals.
Ishigaki, Yasushi; Yamada, Masamichi; Shingaki, Tomotaka; Oura, Tomonori; Shimomura, Iichiro ·
Oral semaglutide: significant AE-related discontinuation predominantly due to GI effects (nausea, vomiting, diarrhea), with patient risk factors identified for predicting discontinuation.
Ishiguro, Mizuki; Nishimura, Rimei ·
Kisspeptin-type peptides are evolutionarily conserved neurohormones controlling reproduction from lamprey to humans, with conserved GnRH stimulation and reproductive maturation functions predating modern vertebrate brain evolution.
Islam, Tabinda; Yañez-Guerra, Luis A; Semmens, Dean C; Beskeen, Riley T; Egertová, Michaela; Elphick, Maurice R ·
GLP-1 RA use associated with reduced RA risk, potentially through immunomodulatory/anti-inflammatory mechanisms beyond weight reduction alone.
Israel, Ariel; Hassan, Fadi; Merzon, Eugene; Kurtam, Jalal; Awad, Jamal; Assalia, Mai; Green, Ilan; Vinker, Shlomo; Naffaa, Mohammad E ·
Tirzepatide use associated with reduced both MACE (cardiovascular events) and MALE (limb events) in patients with atherosclerosis, demonstrating pan-vascular protective effects.
Iwasaki, Yoshihiro; Shimada, Takenobu; Kishimori, Takefumi; Kato, Takao; Koike, Jumpei; Matsumoto, Takehiro; Yagi, Takafumi; Okada, Masaharu ·
Once-weekly semaglutide: sustained HbA1c reduction and weight loss over 12 months in Japanese T2D real-world practice, consistent with clinical trial data. Safe and effective in Asian population.
Iwata, Yoko; Yoshikawa, Fukumi; Saito, Manabu; Fuchigami, Ayako; Sato, Genki; Saiki, Atsuhito; Ichijyo, Takamasa; Sato, Nobuyuki; Ohashi, Tadamasa; Hirose, Takahisa; Uchino, Hiroshi ·
GLP-1 RAs may improve acne (sebaceous/androgen modulation), HS (anti-inflammatory/weight reduction), and psoriasis (immunomodulation) through the metabolic-immune axis connecting obesity/diabetes to inflammatory skin disease.
Jabin, Azra; Khan, Shahab; Khan, Hammad; Durrani, Zain Ullah; Hamza, Khizer; Gul, Faiza; Atta Ullah, Sana; Dayam, Fahad; Yaseen, Muhammad; Shah, Saleem ·
HBD-3 serves as a transcriptional convergence point: directly kills pathogens (innate), activates dendritic cells, modulates T cells, and regulates inflammatory gene expression (adaptive), bridging both immune branches.
Jacobo-Delgado, Yolanda M; Huerta-Elías, Jaime Eduardo; Cabral-Venegas, Valeria; García-Hernández, Mariana; Rivas-Santiago, Bruno ·
Peptide vaccines: precise antigen targeting, safety, scalability for viral pathogens. Advanced delivery (NPs, liposomes, VLPs) and computational design accelerating development. Challenges: immunogenicity, HLA diversity, adjuvant needs.
Jahantigh, Hamid Reza; Rezanavaz Gheshlagh, Solaleh; Mafakher, Ladan; Ahmadi, Nahid; Shahbazi, Behzad; Ahmadi, Khadijeh ·
Preoperative GLP-1/GIP therapy: does not compromise post-bariatric weight loss; may optimize preoperative metabolic status; perioperative management guidelines needed; T2D patient focus.
Jain, Varun; McMullen, Colleen A; Kimbrough, Joy I; Rockich, Anna K; Davenport, Daniel L; Hawk, Gregory S; Nikolajczyk, Barbara S; Kern, Philip A; Fisher, Simon J; Steiner, Joshua P; Inabnet, William B; Starr, Marlene E ·
Comprehensive identification of danuglipron metabolites in vitro and in vivo, characterizing major metabolic pathways for this novel small-molecule oral GLP-1R agonist.
Jaiswal, Anupam; Biradar, Rushikesh; Deshmukh, Vaibhav; Deshpande, Rashmi; Nandi, Sukhendu ·
GLP-1 RAs significantly reduced MACE in T2D patients with high cardiovascular risk.
Jaiswal, Vikash; Mashkoor, Yusra; Borra, Vamsikalyan; Gera, Asmita; Patel, Nirmit; Jitta, Sahas Reddy; Nasir, Yusra Minahil; Sharma, Prachi; Mattumpuram, Jishanth ·
Zavegepant 10 mg nasal: RID <1% (well below 10% safety threshold); peak breast milk at 2-4 hours; rapid decline; supports breastfeeding safety.
Jakate, Abhijeet; Weng, Yan; Shkrodova, Ani; Fisniku, Ogert; Ding, Ding; Morton, Kayce; Maligalig, Benjamin; Garnick, Pamela; Liu, Jing; Shahin, Mohamed H ·
Convergent hybrid synthesis using SPPS fragment preparation + TFF-based assembly achieved gram-scale tirzepatide production, overcoming scalability limitations of traditional synthesis.
Jalan, Ankur; Murzinski, Emily S; Jansen, Patrick J; Miller, Richard D; Embry, Matthew C; Scherer, Roger B; Moomaw, John F; Williams, Katerina M; Fisher, Cyrus A; James, Jinju; Arbour, Christine A; Guinn, Emily J; Teng, Jing; Kopach, Michael E ·
GLP-1 RAs: GI effects (up to 80%), pancreatitis (monitoring needed), thyroid concerns (animal > human data), established CV/renal benefits, emerging safety signals requiring surveillance.
Jalleh, Ryan J; Talley, Nicholas J; Horowitz, Michael; Nauck, Michael A ·
Systematic review reveals critical evidence gaps in RCT reporting of dietary intake and quality changes during GLP-1/GIP therapy, limiting nutritional management guidance.
Jansson, Anna K; Gómez-Martín, María; Hedin, Linnea; Clarke, Erin D; Cross, Victoria; Stanford, Jordan; Taylor, Rachael M; Bogl, Leonie H; De Vlieger, Nienke; Koochek, Afsaneh; Löf, Marie; Asher, Roberta C; Burrows, Tracy; Bucher, Tamara; Sullivan, Clair; Nowicka, Paulina; Collins, Clare E ·
Collagen-encoded α-helical peptides: broad-spectrum antimicrobial activity, low cytotoxicity, low hemolysis. Establishes collagen as a host source of encrypted endogenous AMPs contributing to innate immunity.
Jarmusch, Scott A; Muhammad, Taj; Göransson, Ulf; Strömstedt, Adam A ·
CST ameliorated tauopathy, amyloidogenesis, synaptic dysfunction, and neuroinflammation in AD, CBD, and PSP models through adrenergic signaling inhibition — revealing catecholamine-tau pathology connection.
Jati, Suborno; Kal, Satadeepa; Munoz-Mayorga, Daniel; Tang, Kechun; Sahoo, Debashis; Chen, Xu; Mahata, Sushil K ·
BEVs from S. parauberis efficiently delivered human cathelicidin-derived AMP, enhancing antimicrobial activity compared to free peptide through biological nanocarrier delivery.
Jayathilaka, E H T Thulshan; Dias, Mawallage Kankanamge Hasitha Madhawa; Nikapitiya, Chamilani; De Zoysa, Mahanama ·
Exercise + GLP-1 RA combination effects on physical fitness assessed, informing whether the interventions are additive, synergistic, or competitive for functional outcomes.
Jensen, Simon Birk Kjær; Fiorenza, Matteo; Juhl, Christian Rimer; Sandsdal, Rasmus Michael; Jensen, Emma; Seier, Søren Sonnenborg; Janus, Charlotte; Jørgensen, Julie Rehné; Blond, Martin Bæk; Holst, Jens Juul; Stallknecht, Bente Merete; Madsbad, Sten; Bandholm, Thomas; Torekov, Signe Sørensen ·
SGLT2i and GLP-1 RA showed differential kidney outcome profiles in T2D, with comparative effectiveness varying by baseline kidney function and patient risk characteristics.
Jensen, Simon K; Heide-Jørgensen, Uffe; Andersen, Ina T; Bonnesen, Kasper; Fu, Edouard L; Thomsen, Reimar W; Christiansen, Christian F ·
Zein NPs loaded with anticancer peptides: enhanced stability, cellular uptake, sustained release, and improved anti-tumor activity against HNSCC compared to free peptide.
Jenča, Andrej; Saberian, Elham; Jenčová, Janka; Petrášová, Adriána; Jenča, Andrej; Mills, David; Zare-Zardini, Hadi; Kubíková, Eliška; Dianišková, Simona; Pyndus, Tetyana ·
GLP-1 RA use associated with reduced OA risk in T2D, likely through weight reduction and anti-inflammatory mechanisms.
Jeon, Minjeong; Hong, Bin; Ko, Hwa Yeon; Song, Hong Ji; Kwak, Soo Heon; Kim, Ju Hwan; Shin, Ju-Young ·
CPP-PNA conjugates targeting pdxA gene silenced vitamin B6 biosynthesis in bacteria, demonstrating gene-specific antimicrobial activity through targeted metabolic disruption as a precision antibiotic strategy.
Jeon, Wook-Jong; Seo, Ju Hui; Kim, Yoo Jeong; Bae, Song-Mee; Moon, Dong Chan ·
LTX-315 targets PD-L1 on cancer cells, combining direct oncolytic (membrane-disrupting) activity with immune checkpoint modulation for dual anti-tumor mechanism.
Ji, Kun; Jing, Li; Xu, Tiantian; Cao, Shoujin; Zhang, Cong; Wang, Zilin; Zhou, Guanhui; Cao, Yunbo; Niu, Jiahua; Yang, Yuning; Chen, Xinhua; Ai, Jing; Sun, Jun-Hui; Xiong, Bin ·
Bofanglutide (novel GLP-1 RA): significant weight loss and metabolic improvements with acceptable safety in Chinese adults with obesity.
Ji, Linong; Gao, Leili; Tian, Junhang; Dong, Ruihua; Zhang, Zhongtao; Shu, Hongyan; Zhao, Jing; Zhao, Liyuan; He, Anshun; Xie, Tian; Li, Yue; Chen, Wei ·
Novel α-glucosidase inhibitory peptides purified and identified from Bacillus subtilis-fermented okara, with dose-dependent inhibition supporting antidiabetic nutraceutical development.
Ji, Nairu; Li, Hui-Lin; Ren, Fei; Zhang, Yingqi; Zhao, Bingyu; Chen, Chang; Zhu, Yunping ·
pH-responsive HA hydrogel delivers integrin α5β1-targeting peptides at acidic lesion sites, modulating macrophage M1→M2 polarization to reduce fibrosis and restore uterine tissue in IUA models.
Ji, Wanqing; Wen, Jiaming; Tong, Nian; Guo, Fang; Zheng, Jie; Wen, Xuejun; Liu, Jie; Zhang, Ning; Hou, Bo ·
Peptide-based approaches (AMPs, CPPs, PDCs) address intracellular bacterial infections by combining cell penetration, antimicrobial activity, and immunomodulation to reach pathogens hidden inside host cells.
Jiang, Jun; Qi, Yunkun; Ma, Shutao ·
Liraglutide prevented lupus-associated DAH in a mouse model by inhibiting inflammatory signaling pathways, demonstrating novel autoimmune lung protection by a GLP-1 RA.
Jiang, Li; He, Liting; Li, Duo; Luo, Xin; Yang, Ming; Wu, Haijing; Long, Hai ·